Drug therapy in schizophrenia.

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Medicine

Background:

• Over 40 antipsychotic medications exist globally, with 21 available in the U.S.
• Conventional antipsychotics (late 1950s) present efficacy and safety concerns.
• Atypical antipsychotic agents (AAP) exhibit higher 5-HT(2) than D(2) blocking, with varying receptor actions and side effect profiles.

Purpose of the Study:

• To review the efficacy and safety profiles of various antipsychotic medications.
• To discuss the role of antipsychotics in managing acute psychotic states and preventing relapse.
• To highlight differences in receptor actions and side effect profiles among atypical antipsychotic agents.

Main Methods:

• Comparative analysis of antipsychotic drug classes (conventional vs. atypical).
• Review of receptor binding profiles (5-HT(2) and D(2) blocking).
• Evaluation of clinical use in acute settings and long-term relapse prevention.

Main Results:

• Clozapine demonstrates superior efficacy; clozapine and olanzapine are associated with weight gain and potential diabetes.
• Quetiapine requires careful titration for acute states; ziprasidone and aripiprazole are less sedating and have not been linked to weight gain or diabetes.
• Antipsychotic monotherapy is preferred in acute settings; AAP drugs avoid acute extrapyramidal symptoms (EPS).

Conclusions:

• Intramuscular haloperidol and ziprasidone may be needed for acute psychosis management.
• The primary goal of acute treatment is symptom reduction to prevent self-harm or harm to others.
• Long-term, indefinite treatment with the minimum effective antipsychotic dose is recommended to prevent relapse.